Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (201-210 of 212) with videos related to

Pageof 22
Sort By:
The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Nature Biotechnology|November 2, 2021
Improved prediction of immune checkpoint blockade efficacy across multiple cancer typesDiego Chowell, Seong-Keun Yoo, Cristina Valero, et al.
Nature|April 12, 2017
T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseAlexander C Huang, Michael A Postow, Robert J Orlowski, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyMichael A Postow, Peter D Zang, Sumanta K Pal, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Nature Methods|April 11, 2025
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profilingAlexandre Pellan Cheng, Adam J Widman, Anushri Arora, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
Nature Medicine|June 14, 2024
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichmentAdam J Widman, Minita Shah, Amanda Frydendahl, et al.
Pageof 22

Showing results (201-210 of 212) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|June 2, 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
The New England Journal of Medicine|September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Nature Biotechnology|November 2, 2021
Improved prediction of immune checkpoint blockade efficacy across multiple cancer typesDiego Chowell, Seong-Keun Yoo, Cristina Valero, et al.
Nature|April 12, 2017
T-cell invigoration to tumour burden ratio associated with anti-PD-1 responseAlexander C Huang, Michael A Postow, Robert J Orlowski, et al.
Journal for Immunotherapy of Cancer|March 27, 2026
CD8 PET imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate studyMichael A Postow, Peter D Zang, Sumanta K Pal, et al.
The Lancet. Oncology|July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma ConsortiumRodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Nature Methods|April 11, 2025
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profilingAlexandre Pellan Cheng, Adam J Widman, Anushri Arora, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
Nature Medicine|June 14, 2024
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichmentAdam J Widman, Minita Shah, Amanda Frydendahl, et al.
Pageof 22